1. Lazzeri C., Sori A., Chiostri M., Gensini G.F., Valente S. Prognostic role of insulin resistance as assessed by homeostatic model assessment index in the acute phase of myocardial infarction in nondiabetic patients submitted to percutaneous coronary intervention // Eur. J. Anaesthesiol. 2009. Vol. 26. Р. 856–862.
2. Rask-Madsen C., Kahn C. Tissue-specific insulin signaling, metabolic syndrome, and cardiovascular disease // Arterioscler. Thromb. Vasc. Biol. 2012. Vol. 32. Р. 2052–2059.
3. Katz A., Nambi S.S., Mather K., Baron A.D., Follmann D.A., Sullivan G., Quon M.J. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans // J. Clin. Endocrinol. Metab. 2000. Vol. 85. Р. 2402–2410.
4. Gruzdeva O., Uchasova E., Dyleva Y., Belik E., Kashtalap V., Barbarash O. Relationship between free fatty acids, insulin resistance markers, and oxidized lipoproteins in myocardial infarction and acute left ventricular failure // Diabetes Metab. Syndr. Obes. 2013. Vol. 6. Р. 103–111.
5. Lee H.M., Wang G., Englander E.W., Kojima M., Greeley G.H. Jr. Ghrelin, a new gastrointestinal endocrine peptide that stimulates insulin secretion: Enteric distribution, ontogeny, influence of endocrine, and dietary manipulations // Endocrinology. 2002. Vol. 143. Р. 185–190.
6. Yada T., Dezaki K., Sone H., Koizumi M., Damdindorj B., Nakata M., Kakei M. Ghrelin regulates insulin release and glycemia: physiological role and therapeutic potential // Curr. Diabetes. Rev. 2008. Vol. 4. Р. 18–23.
7. Blom W.A., Stafleu A., de Graaf C., Kok F.J., Schaafsma G., Hendriks H.F.J. Ghrelin response to carbohydrate- enriched breakfast is related to insulin // Am. J. Clin. Nutr. 2005. Vol. 81. P. 367–375.
8. Doogue M.P., Begg E.J., Moore M.P., Lunt H., Pemberton C.J., Zhang M. Metformin increases plasma ghrelin in type 2 diabetes // Br. J. Clin. Pharmacol. 2009. Vol. 68. Р. 875–882.
9. Sinha D.P., Ahmed S., Baneerjee A.K., Das M., Hassan H. Significance of an index of insulin resistance in non-diabetic patients with impaired fasting glucose with acute myocardial infarction and its correlation to short term outcome // Indian Heart J. 2009. Vol. 61 (1). Р. 40–43.
10. Альмухамбетова Р.К., Жангелова Ш.Б., Токсанбаева Г.Т., Мусаев А.А., Кодасбаев А.Т., Мусаев А.Т., Оспанов Б.Ж., Альмухамбетов М.К., Жангелова М.Б., Рустамова Ф.Е., Арипов М.А., Ералиева Л.Т., Батырбаева Д.Ж., Ложкин А.А., Бекту- раева С.У. Синдром инсулинорезистентности у больных кардиологического профиля // Соврем. пробл. науки и образования. 2016. (3). URL: http://www.science-education.ru/ru/article/view?id=24413(дата обращения: 21.06.2019).
11. Clavijo L.C., Pinto T.L., Kuchulakanti P.K., Torguson R., Chu W.W., Satler L.F., Kent K.M., Suddath W.O., Pichard A.D., Waksman R. Metabolic syndrome in patients with acute myocardial infarction is associated with increased infarct size and in-hospital complications // Cardiovasc. Revasc. Med. 2006. Vol. 7 (1). Р. 7–11.
12. Timmer J.R., Ottervanger J.P., de Boer M.J., Dambrink J.H., Hoorntje J.C., Gosselink A.T., Suryapranata H., Zijlstra F., van 't Hof A.W. Hyperglycemia is an important predictor of impaired coronary fl ow before reperfusion therapy in ST-segment elevation myocardial infarction // J. Am. Coll. Cardiol. 2005. Vol. 45, N 7. Р. 999–1002.
13. Vestergaard E.T., Hansen T.K., Gormsen L.C., Jakobsen P., Moller N., Christiansen J.S., Jorgensen J.O. Constant intravenous ghrelin infusion in healthy young men: clinical pharmacokinetics and metabolic effects // Am. J. Physiol. Endocrinol. Metab. 2007. Vol. 292. Р. E1829–E1836.
14. Guido M., Romualdi D., de Marinis L., Porcelli T., Giuliani M., Costantini B., Lanzone A. Administration of exogenous ghrelin in obese patients with polycystic ovary syndrome: effects on plasma levels of growth hormone, glucose, and insulin // Fertil. Steri. 2007. Vol. 88. Р. 125–130.
15. López M., Lage R., Saha A.K., Pérez-Tilve D., Vázquez M.J., Varela L., Sangiao-Alvarellos S., Tovar S., Raghay K., Rodríguez-Cuenca S., Deoliveira R.M., Castañeda T., Datta R., Dong J.Z., Culler M., Sleeman M.W., Alvarez C.V., Gallego R., Lelliott C.J., Carling D., Tschöp M.H., Diéguez C., Vidal-Puig A. Hypothalamic fatty acid metabolism mediates the orexigenic action of ghrelin // Cell Metab. 2008. Vol. 7. Р. 389–399.
16. van der Lely A.J., Tschop M., Heiman M.L., Ghigo E. Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin // Endocr. Rev. 2004. Vol. 25. Р. 426–457.
17. Chang L., Ren Y., Liu X., Li W.G., Yang J., Geng B., Weintraub N.L., Tang C. Protective effects of ghrelin on ischemia/reperfusion injury in the isolated rat heart // J. Cardiovasc. Pharmacol. 2004. Vol. 43. Р. 165–170.
18. Marchesini G., Pagotto U., Bugianesi E., de Iasio R., Manini R., Vanni E., Pasquali R., Melchionda N., Rizzetto M. Low ghrelin concentrations in nonalcoholic fatty liver disease are related to insulin resistance // J. Clin. Endocrinol. Metab. 2003. Vol. 88 (12). P. 5674–5679.
19. Schaller G., Schmidt A., Pleiner J., Woloszczuk W., Wolzt M., Luger A. Plasma ghrelin concentrations are not regulated by glucose or insulin: a double-blind, placebo-controlled crossover clamp study // Diabetes. 2003. Vol. 52 (1). Р. 16–20.
20. Qarni A., Joatar F., Das N., Awad M., Eltayeb M., Al-Zubair A., Ali M., Masaud A., Shire A., Gumaa K., Giha H. Association of plasma ghrelin levels with insulin resistance in type 2 diabetes mellitus among Saudi subjects // Endocrinol. Metab (Seoul). 2017. Vol. 32 (2). Р. 230–240.